Enhanced T-cell therapy targeting NY-ESO-1 regulatory update

Adaptimmune said EMA granted PRIority MEdicines (PRIME) designation to its enhanced T-cell therapy targeting NY-ESO-1 to treat inoperable or metastatic synovial sarcoma that expresses cancer/testis a...